Structure matters because it determines how molecules fit together
Inside every living cell, a molecular conversation unfolds between messenger RNAs carrying genetic instructions and microRNAs that silence them — a dialogue whose misreading underlies diseases like cancer. Researchers at Université de Montréal have now built RIMap-RISC, the first systematic platform to map these interactions using not just genetic sequence but the actual three-dimensional shapes of the molecules involved. Released as an open-access tool with a programmable interface, it represents less a discovery than a foundation — the kind of shared infrastructure that quietly makes the next generation of discoveries possible.
- Gene regulation depends on microRNAs finding and silencing the right messenger RNAs, but until now no tool could model this process with both structural and sequence precision.
- When this molecular recognition system fails, the consequences can be catastrophic — cancer and other complex diseases often trace back to exactly this kind of regulatory breakdown.
- Ph.D. student Simon Chasles and professor François Major at Université de Montréal built RIMap-RISC to fill that gap, weaving three-dimensional molecular structure into the analysis for the first time systematically.
- The platform is freely accessible online with a programmable interface, allowing researchers worldwide to integrate it into their own computational pipelines and build new tools on top of it.
- The tool is already positioned to accelerate research into cancer biology, RNA engineering, and gene regulation — not as a final answer, but as shared infrastructure for thousands of future questions.
At Université de Montréal's Institute for Research in Immunology and Cancer, a team has built something researchers have long needed: a systematic way to observe how two types of RNA molecules find and interact with each other inside living cells. The tool, called RIMap-RISC, emerged from the work of Ph.D. student Simon Chasles under the direction of computer science professor François Major, and their findings appear in Genome Biology.
Messenger RNA carries instructions from DNA to the cell's protein-making machinery. MicroRNA does something different — these short molecules hunt down specific messenger RNAs and silence them, preventing certain genes from ever becoming proteins. This regulation is essential to healthy cell function, and when it breaks down, disease follows.
Previous efforts to map these interactions relied on sequence data alone — the order of chemical bases in the RNA. What Major's team did differently was incorporate the actual three-dimensional structure of the molecules. Structure determines how molecules recognize and fit together, and by integrating it with sequence data, the researchers created a far more complete model of microRNA-messenger RNA interaction across both healthy and diseased states. "This is the first time such modeling has been done systematically," Major noted.
The platform is freely accessible and comes with a programmable interface, allowing other scientists to plug it into their own computational workflows and build new tools on top of it. Researchers studying basic gene regulation, as well as those investigating cancer, can use RIMap-RISC to test hypotheses and trace which microRNAs are misbehaving and why.
Major framed the tool not as an endpoint but as infrastructure — the kind that enables data reuse, integration into existing pipelines, and entirely new approaches in RNA biology. RIMap-RISC is, in other words, the quiet foundation on which the next generation of discoveries will be built.
At Université de Montréal's Institute for Research in Immunology and Cancer, a team has built something that researchers have long needed: a systematic way to watch how two types of RNA molecules find each other and interact inside cells. The tool is called RIMap-RISC, and it emerged from the work of Ph.D. student Simon Chasles under the direction of François Major, a computer science professor who runs the institute's RNA engineering research unit. Their findings appear in Genome Biology.
To understand what makes this work significant, you need to know what these molecules do. Messenger RNA carries instructions copied from DNA and delivers them to the protein-making machinery in the cell. MicroRNA is different—these are short molecules that hunt down specific messenger RNAs and either destroy them or silence them, effectively preventing certain genes from being translated into proteins. This silencing is crucial. It's how cells regulate themselves, and when it goes wrong, disease can follow.
Previous attempts to map these interactions relied on sequence information alone—essentially, the order of chemical bases in the RNA molecules. What Major's team did differently was incorporate the actual three-dimensional structure of these molecules. Structure matters because it determines how molecules fit together, how they recognize each other, and ultimately whether an interaction will happen at all. By integrating structural data with sequence data, the researchers created a model that captures the full picture of how microRNAs and messenger RNAs recognize and regulate each other, whether in healthy cells or in disease states like cancer.
"This is the first time such modeling has been done systematically," Major said. The distinction is important. Researchers have studied these interactions before, but never with this level of systematic rigor, never with structure woven throughout, never in a way that could be applied broadly across different biological contexts.
The platform itself is freely accessible online and comes with a programmable interface—meaning other scientists can plug it into their own computational pipelines, extract data from it, and build new tools on top of it. This is how modern biology moves forward: not through isolated discoveries, but through shared infrastructure that lets thousands of researchers ask their own questions.
The applications are immediate and wide-ranging. Basic researchers studying how cells regulate gene expression can use RIMap-RISC to test hypotheses. Scientists investigating cancer, where gene regulation often goes catastrophically wrong, can search the database to understand which microRNAs are misbehaving and why. The tool promises to accelerate the pace at which researchers can move from observation to insight to intervention.
Major framed it in terms of what comes next: the database will encourage data reuse, integration into existing bioinformatics workflows, and the development of entirely new research approaches in RNA biology. In other words, RIMap-RISC is not an endpoint. It's infrastructure—the kind of thing that quietly enables the next generation of discoveries.
Notable Quotes
This is the first time such modeling has been done systematically.— François Major, director of IRIC's RNA engineering research unit
Our new tool will promote the reuse of data, its integration into bioinformatics pipelines, and the development of new approaches to research and innovation in RNA biology.— François Major
The Hearth Conversation Another angle on the story
Why does structure matter so much more than sequence when we're talking about how these molecules interact?
Because two molecules can have the same sequence but fold differently in space. If they don't fold the right way, they can't recognize each other. It's like having the same letters but arranging them so they don't spell the word anymore.
So previous databases were essentially incomplete?
Not incomplete—they were working with what they had. But yes, they were missing a whole dimension of information. It's the difference between knowing someone's name and knowing what they look like.
What does this mean for someone working on cancer?
It means you can now ask: which microRNAs should be active in a healthy cell, and which ones are going rogue in this tumor? And you can see structurally why they're misbehaving, not just that they are.
Is this tool ready to use right now?
It's online and open-access. Researchers can start using it today. But the real value will emerge as people integrate it into their own work and build new tools on top of it.
What's the biggest limitation?
It's still a model. The real cell is messier and more complex than any database can capture. But it's a much better starting point than we had before.